analyticsinsight.net
Oct 6, 2026
eIFU Requirements in 2026: FDA eLabeling, EU MDR and the 2025 Amendment, Plus 8 eIFU Services Compared
AI-summarised brief · reviewed before publication
In 2026, medical device manufacturers must comply with two regulatory frameworks: the EU’s Regulation (EU) 2021/2226, amended by Regulation (EU) 2025/1234, and the U.S. FDA’s section 502(f) of the Federal Food, Drug, and Cosmetic Act. The article lists eight eIFU services—Matrix eIFU, DocuLiv, eIFU.com, RealBit MEDELIA, eIFUApp, Alysidia, Cognidox, and NPG—that meet both sets of requirements. Key provisions include mandatory paper copies within seven days, 10‑year online retention, multilingual support, and ISO 13485‑based validation. The piece outlines steps for risk assessment, UDI‑DI mapping, and parallel system operation during validation.
💡 Why It Matters
- · The dual‑regulation alignment forces manufacturers to adopt robust, cross‑border eIFU solutions, tightening patient safety and streamlining compliance across markets.
